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Abstract
In searching for remedial etiologies for congenital heart disease (CHD), we have
focused on identifying interactive signaling pathways or “hubs” in which
mutations disrupt fundamental cell biological functions in cardiac progenitor
cells in a lineage-specific manner. Based on the frequency of heart defects seen
in a clinical setting, we emphasize two signaling hubs – nodal kinases activated
by extracellular ligands (e.g., periostin) and the cytoskeletal regulatory protein,
filamin A (FLNA). We discuss them in the context of valve and septal develop-
ment and the lineages which give origin to their progenitor cells. We also
explore developmental windows that are potentially amenable to remedial
therapy using homeostatic mechanisms like those revealed by a chimeric mice
model, i.e., irradiated animals whose bone marrow had been reconstituted with
GFP+ hematopoietic stem cells, that shows bone marrow-derived cells track to
the heart, engraft, and give rise to bona fide fibroblasts. We propose to use this
model to deliver genetic payloads or protein cargos during the neonatal period to
override biochemical or structural deficits of CHD associated with valve and
septal signaling hubs or fibroblast/myocyte interactions. Preliminary tests of the
model indicate remedial potential for cardiac injuries.
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Etiologies of congenital heart defects have been difficult to identify and explain,
often invoking discussions of genetics and environment or both. After 40+ years of
searching for etiologies, especially ones that might be potentially remedial, a few
conceptual observations are emerging (although by no means is there consensus).
These include suppositions that:
1. Genetics more than environment is responsible for CHD based on the ability to
simulate human heart congenital defects in animal genetic models (see also
Bhattacharya [1]).
2. The evolution of genetic thought is toward trans-heterozygous, multigenetic
interactions vs. single gene hits.
3. Mutations in the downstream intracellular signaling targets of growth factor,
transcription factors, or matricellular proteins are more likely to be the root
cause of heart defects seen in children by pediatric cardiologists (as the loss of
both alleles for upstream early regulatory genes is usually lethal).
4. Intersecting regulatory networks or signaling hubs coordinate fundamental
biological processes in cardiac progenitor cells in a lineage-restricted manner.
5. Based on the frequency of different types of heart defects, the lineages most
likely to be modified by genetic mutations or environmental stressors in CHD
are the non-cardiomyocyte lineages, primarily fibroblasts.
5.1.2 Hub Hypothesis
In trying to provide answers to the questions most often asked by parents of children
born with heart defects – “why did it happen?” and “what can be done about it?” –
we have endeavored to integrate these five emerging concepts around two examples
of central signaling hubs or platforms that intersect with multiple gene regulatory
networks (like the spokes of a wheel) to regulate or “tune” behavioral changes in the
progenitor cells engaged in valvuloseptal morphogenesis (or myocardial
remodeling). In so doing, we propose that intersecting signaling hubs explain
why so many different genes, if mutated or deleted, can engender similar
anatomical dysmorphic phenotypes, e.g., ventricular septal defects. This suggests
that there are only so many ways progenitor cells can respond to normal or
abnormal signaling inputs: e.g., they can proliferate, activate, or suppress apoptotic
pathways; transport ions; secrete, endocytose, adhere/migrate, and generate con-
tractile forces; change polarity or shape; and differentiate. Thus, the conceptual
appeal of common final pathways or intersecting signaling hubs/nodes is that they
provide potential for exploring “shared” remedial therapies for CHD that do not
require an individual approach for correcting each abnormal gene.
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5.2 Searching for Candidate Signaling Hubs in Heart
Development
5.2.1 Nodal Signaling Kinases
In patients with Down, Marfan, or Noonan Syndromes, there is increasing evidence
that genes encoding nodal signaling kinases like FAK/AKTkt/PI3K, RAS, MEKK/
ERK1/2, PTPN11, etc., are likely candidates for CHD if they are mutated or
overexpressed [2–4]. Such genes are not usually lethal (as there exist molecular
or functional redundancies), yet as indicated for syndromic heart defects, they have
potential to change functional behaviors in progenitor cells that normally mold and
remodel the simple tubular heart into a four-chambered organ. As indicated in
Fig. 5.1, intracellular signaling kinases (and small regulatory GTPases) are the
direct and indirect downstream targets of growth factors (e.g., TGFβ and BMP
2&4) that are normally secreted by the embryonic endocardium or myocardium [5],
or in the case of extracellular ligands like matricellular proteins (periostin, the CCN
family), they are secreted by the mesenchymal progenitor cells of valves and
connective septa which are derived from both endocardium and epicardium
[6]. In the case of matricellular and other extracellular proteins (Fig. 5.2), binding
to integrin receptors triggers integrin-dependent, downstream signaling kinases/
GTPases (FAK/AKT/PI3k) which activate effector mechanisms of growth, sur-
vival, and differentiation into the fibrous structures (valves and septa) that assure
coordinated and unidirectional blood flow through the right and left sides of the
developing heart. Epicardial-derived mesenchymal cells also express periostin as
they invade the ventricular myocardium and, like endothelial-derived mesenchyme,
secrete collagen and differentiate into ventricular connective tissue but also con-
tribute to the parietal leaflets of the AV valves [7, 8]. Disruption of these signaling
pathways by either silencing one or more of the kinases shown in Fig. 5.1, inhibiting
β-integrin functions, or deleting the periostin gene itself resulted in septal defects,
abnormal (poorly differentiated, hypertrophic) valves, arrhythmias associated with
a reduction in the AV fibrous connective tissue, and a reduction in ventricular
elastic modulus due to loss of interstitial collagen [9, 10]. These findings are
consistent with the relevance of central or nodal signaling kinases to heart develop-
ment and how different genes, if mutated or inhibited, could produce similar
abnormal anatomical phenotypes as a result of either binding to, activating, or
encoding a kinase or GTPase component of an interactive signaling pathway.
Conceivably, these same interactive signaling pathways could also be used to
explore remedial therapies for CHD. Any one or combination of the signaling
kinases or effector proteins shown in Fig. 5.1 could be a candidate therapeutic
target that could be used to bypass or circumvent a genetic or biochemical block
associated with a particular CHD, if a way could be found to administer drugs or
small molecules that silence, simulate, or activate them. Identifying an in utero
approach using orally administered or injected signaling inhibitors, lithium, or
retinoids is appealing but lacks target specificity (potentially engendering a broad
spectrum of side effects), or it can create a catch-22 in the sense that treatments may
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have to begin too early, i.e., before it can be actually determined that a development
defect is going to happen. Genetic rescues can identify and test candidate target
mechanisms (e.g., breeding Noonan mice into an Erk null background) but have
little practical remedial potential for preventing CHD.
Another plus for interactive signaling hubs is their potential to reveal a new or
unexpected “spoke” whereby genetic, protein, or biochemical connections to sig-
naling pathways are not readily apparent or known, e.g., hyaluronan synthetase
2 (Has2). As shown by Misra et al. [6], Has2 is activated by nodal kinases that are
regulated by periostin-integrin-linked signaling [6]. Phosphorylation of Has2 leads
to secretion of hyaluronan (HA) (Fig. 5.1, right) which, in addition to its osmotic
properties, also binds to CD44, a tyrosine kinase receptor for HA that is expressed
by valvular-septal mesenchymal progenitor cells [11]. Binding of HA to CD44
activates some of the same kinases also activated by periostin-integrin signaling,
thereby triggering positive feedback loops that can amplify or sustain shared
biological effects of periostin including formation, migration, and survival of
progenitor valvuloseptal mesenchyme as well as a positive feedback on the secre-
tion of periostin itself (Fig. 5.1) [6, 11]. CD44 signaling also appears to be part of a
signaling complex revealed by immunoprecipitation that is required for periostin to
activate another candidate signaling hub – filamin A (Fig. 5.2).
Fig. 5.1 (Left): Generalized model proposing the candidate genes for CHD. Based on syndromic
mutations or overexpression, the model proposes that the most likely candidates are genes that
encode components of a signaling hub such as the one shown for an extracellular ligand and
membrane receptors. Their interaction activates a cascade of nodal kinases within valvuloseptal
progenitor cells that regulate biological functions in progenitor cells that are normally associated
with remodeling the primary heart into a four-chambered organ. (Right): Periostin-integrin model
depicting downstream targets activated by periostin binding to specific β-integrin heterodimeric
receptors expressed in valve and septal progenitor cells. Based on published results [6], periostin
binding to integrin induces phosphorylation of p-FAK (a nodal kinase) which, in turn, activates
different signaling pathways, p-AKT/PI3K and/or p-Erk, each with distinct biological activities;
e.g., p-AKT/PI3K promotes hyaluronan (HA) secretion and enhances periostin expression,
whereas Erk activates collagen secretion and survival (anti-apoptotic) mechanisms
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5.2.2 Filamin A
Filamin A (FLNA) is a homo- or heterodimeric Y-shaped cytoplasmic protein in
which each main chain consists of an actin-binding region at the amino terminus, a
core of 24 highly homologous Ig-like repeats followed by a carboxyl integrin-
binding domain. The most widely studied function of FLNA is its ability, upon
activation, to self-assemble into signaling scaffolds or to cross-link cortical actin
filaments into a dynamic three-dimensional structure [12]. In the developing heart,
FLNA can promote or suppress cell processes important for heart development as
evident that when the gene is deleted, lethality ensues. Through its role as an actin-
binding protein that anchors various transmembrane proteins to the cytoskeleton, it
can generate contractile forces to support migration and fusion of the paired midline
AV mesenchymalized “cushions” to form the AV septum [13]. Upon activation, the
scaffolds assembled by FLNA form docking sites for second messengers like smad
2/3 which are critical for transmitting TGFβ signaling in heart development
[14, 15]. While FLNA is also expressed in the brain and other organs, it is
specifically expressed in the heart in valvuloseptal mesenchyme derived from the
endocardium and epicardium [16]. The null phenotype, although lethal at ED15.0,
is consistent with the pattern of FLNA expression in valvuloseptal primordia, i.e.,
there are septal and valve defects at all axial levels: atrial, atrioventricular, ventric-
ular, and outlet [15–17].
FLNA itself responds to many signaling “inputs” that can activate FLNA or
modify its binding to actin [18], including Ras and Rho kinase. Immunoprecipita-
tion studies confirmed that FLNA is also a downstream target of kinases induced by
periostin-integrin signaling that promote the binding of PAK-1 to FLNA, resulting
in its activation (Fig. 5.2). A large primary atrial septal defect is seen in periostin
Fig. 5.2 Coordinated activation of Filamin and p21-activated kinase 1 (PAK1) by periostin/β1-
integrin signaling in E16.5 mouse AV cells. (a) Representative Western blot for periostin (PN),
p-filamin A (ser 2152), and filamin A from lysates prepared from isolated mouse E16.5 AV valve
cells, transfected with vector controls, PN cDNA, PN-siRNA, and CD44 siRNA for 48 h or treated
with 5 μg/ml β1-integrin-antibody for 24 h. (b) Same protocol as A but lysates were immunopre-
cipitated with filamin A and binding proteins in the immunoprecipitate were immunoblotted. The
figure shows that upon activation, phospho-PAK1 (ser144) binds to Filamin (and transfers its
phosphate to activate the FLNA protein). Because silencing CD44 prevented binding of PAK1 to
FLNA, we have suggested that CD44 forms a signaling complex with periostin-integrin-FAK that
is required for activating FLNA through PAK1
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null mice [19] that is also seen in FLNA nulls, suggesting an interaction between
“signaling hubs” that (normally) promote: (1) fusion of paired mesenchymal
primordia (often called “cushions”) to form septal and valvular primordia and
(2) remodeling of the fused cushion primordia during fetal and early postnatal
life into mature leaflets or tendon-like septal structures.
Loss-of-function, point mutations in FLNA have also been found in patients with
mitral valve disease (e.g., prolapse), all of which occurred in the actin-binding
domains of FLNA and similarly effected cell signaling pathways or cytoskeletal
organization [20]. For example, a G288R and P637Q point disrupted a signaling
network that balanced RhoA and Rac1 GTPases activities and correlated directly
with inhibited cell spreading, migration, and contractile force generation [21]. The
G288R and P637Q mutation also interfered with FLNA’s normal capabilities to
promote the expression and transport of beta integrins to the cell surface or bind a
variety of intracellular target proteins including vimentin and transglutaminase
2 (TG2) [16, 22]. We found that TG2 homeostatically functions to covalently link
serotonin to FLNA enhancing its potential to bind cytoskeletal F-actin and generate
contractile forces related to or required for remodeling of valve primordia into
compacted, sculpted leaflets [16].
FLNA expression, like periostin, peaks in the postnatal period but is barely
detectable in adult heart tissues unless there is an injury ([17, 19, 23]). These
findings have three implications: (1) heart development is not over at birth;
(2) the postnatal period may still be an open window to explore remedial therapies
for CHD, particularly for valve and septal defects [24, 41]; and (3) mutations in
genes that cause abnormal structural or functional changes in heart tissues may not
always be immediately visible at birth but progressively appear over time
[25]. Thus, some “adult cardiovascular degenerative diseases” may actually have
an embryonic developmental etiology [26].
5.2.3 Relevance of Signaling Hubs to CHD
Shared (interconnected) protein signaling hubs point to a multiplicity of ways by
which seemingly unrelated genes (including ones yet to be identified) can converge
to engender anatomically similar developmental heart defects [27, 28]. Understand-
ing these mechanistic relationships will be important as they have realistic remedial
potential for identifying candidate approaches for preventing, modifying, or even
reversing some of the clinical consequences of CHD, particularly if they are
recognized early in the neonatal period. For example, AV valves in which there
is diminished function of FLNA are enlarged at birth (and mesenchymal-like) but
have elevated phosphorylation of ERK1/2 (16, unpublished data) which progres-
sively leads to a more pronounced degenerative, myxomatous-like phenotype. A
potential remedial therapy would be to find a way to attenuate ERK signaling and
assess whether progression to a degenerative phenotype could be delayed or even
reversed. A precedent for this would be the fibrillin-1 knockin model of Marfan
syndrome in which the valves become myxomatous or the Loeys-Dietz mice with
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mutated TGFβ receptors in which the aortic root is dilated and prone to aneurysm
[29, 30]. ERK 1/2 pathways are used in both syndromes to transduce elevated,
noncanonical TGFβ signaling. Pharmacological approaches (e.g., Losartan) to
blunt ERK signaling in both syndromes have improved their cardiovascular func-
tion and tissue structural integrity [30]. In a related fashion, understanding that TG2
promotes serotonylation of FLNA (and its binding affinity for actin), altering
serotonin uptake, and/or synthesis could also prove to be new remedial approaches
for treating valve and septal structural defects during the neonatal period when they
normally complete their maturation. The key would be to identify a means or route
for delivering these potential remedial therapies to the “right cell targets” at the
“right time”.
5.3 Lineage Is a Key to Remedial Therapy
Finding the “right cell targets” for remedial therapy is a question of lineage. Any
hope of efficacious remedial treatments would seemingly require that treatments be
directed to those cell populations that are normally involved in valve and septal
formation and, if mutated, result in CHD. In heart development, it is the
non-myocyte – mostly fibroblast – populations of the heart that appear to be the
critical players in valvuloseptal morphogenesis. They are the only heart progenitor
cells to express the extracellular signaling ligands like periostin or the cytoskeletal
regulatory protein like FLNA. The progenitors of fibroblasts, as noted above, are
the mesenchymal stem cells (or “cushion” cells) derived from the transformation of
two epithelia: endocardium and epicardium. Cells derived from either lineage have
the potential to differentiate into fibroblasts by autonomously secreting periostin
[31, 32]. Thus, cardiac fibroblasts are derived from at least two origins which are
carried over from intrauterine to postnatal and adult life [32]. This raises two
questions: (1) Are new fibroblast progenitor cells added to the heart after birth?
(2) If so, are the same signals (e.g., periostin) used to direct their progression into a
cardiac fibroblast lineage during embryonic life also used postnatally? The answers
to both questions appear to be “yes.”
5.3.1 Postnatal Origin of Cardiac Fibroblasts
Recent single cell engraftment experiments indicate that in postnatal and adult life,
cardiac fibroblasts are also derived from bone marrow or from pericytes that
express the hematopoietic stem cell marker – CD45 [33–38]. In these experiments,
adult mice were lethally irradiated and a single (or clone) of a rigorously isolated
wild-type CD45+ hematopoietic stem cell (HSC) carrying a green fluorescent
protein (GFP) marker was injected into their tail vein. Mice which survived clearly
had received a true multipotential stem cell capable of restoring the blood cell
lineages. We then asked if any of the original clones of CD45+/GFP+ HSCs left the
bone marrow and engrafted elsewhere. They did. We found that CD45+/GFP+ cells
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migrate and engraft in several organs including the heart. Specifically they
engrafted into the inlet and outlet valves, ventricular fibrous interstitium, and as
pericytes surrounding coronary microvasculature [36, 37]. In addition to the CD45
marker and GFP, they also expressed fibroblast markers, e.g., collagen-1, HSP47,
vimentin, discoid domain receptor 2 (DDR2), and, importantly, periostin
[33, 37]. This suggested to us that cardiac fibroblasts are a renewable cell popula-
tion that can be replenished homeostatically by circulating progenitor cells of bone
marrow, HSC origin. Based on marker expression, monocytes are probably the
immediate circulating progenitors of the CD45+/collagen I+ cells that engraft into
the heart, probably as “blank” cells that differentiate into fibroblasts [38, 39]. Impor-
tantly, their numbers increase in the valves and ventricular interstitium significantly
if the heart was injured by coronary ligation or cryoablation, indicating that they are
also a population of fibrogenic precursors that can respond dynamically to injury or
inflammatory signals [38, 40]. In quantitative terms, bone marrow-derived cells
accounted for 20–30 % of fibroblasts in normal adult myocardial tissue [36, 37,
39]. In contrast, we found GFP+ label in myocytes at exceedingly low frequency
[36] making this approach suitable for a targeted assessment of non-myocyte
contributions to cardiac structure and function. It is important to recall, in this
context, that not all lineage markers of hematopoietic cell sources (e.g., CD34) are
applicable across species.
5.3.2 A Strategy to Use Fibroblast Progenitors to Carry Genetic
Payloads
The bone marrow origin of postnatal cardiac fibroblasts does not in any way
exclude new fibroblasts arising by proliferation from lineages carried over from
intrauterine life. However, those fibroblasts would be expected to continue to carry
forward any mutations or other functional or biochemical deficits from embryonic
life, whereas those derived from bone marrow provide an opportunity to be isolated
and genetically or pharmacologically manipulated (or reengineered) and then
returned to the marrow. Thus, we propose to use these fibrogenic CD45+
progenitors to carry genetic payloads (or protein cargos) to sites where fibrous
valvuloseptal or interstitial tissues are underdeveloped or hyperplastic or where
maturation (e.g., valves) has been delayed. Genetic reengineering theoretically
could be done to benefit the health of the newborn with a cardiac developmental
defect at any time or age, but given its potential for regeneration, earlier in the
postnatal period would appear to be the “right time” to implement remedial
therapies before “wet cement becomes hardened” [41].
5.3.2.1 This Strategy Calls for a Conceptual Revision in Our Thinking
About Fibroblasts
This strategy calls for a conceptual revision in our thinking about fibroblasts that
recognizes that they are a renewable cell source that can form a community of
active modulators of cell behaviors that can change cardiac function. The full story
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of cardiac fibroblasts is yet to be realized as to their function in health and disease
including CHD. Already much is being learned about their potential for repair
through homotypic interactions or heterotypic interactions with myocytes. Modes
of contact between fibroblasts or fibroblasts and myocytes include connexin-based,
gap junctions through which ions or small molecules (microRNAs) can be trans-
ferred [42], tunneling nanotubes [43] through which mitochondria can be
exchanged, or by paracrine secretions of cytokines, growth factors, or matricellular
proteins that facilitate their engraftment, proliferation, and/or differentiation [44].
5.4 Remedial Therapies: Delivering Genetic “Payloads”
Our basic premise is that bone marrow-derived fibroblasts make homeostatic
contributions to the non-myocyte cells of adult heart valve and septal connective
tissues. We propose to exploit our findings using the single cell engraftment model
to deliver relevant payloads to connective tissues of hearts with visible congenital
malformations, e.g., valves, septa, hypoplastic ventricles, or non-compacted myo-
cardium in which growth has been compromised. We include myocardial growth
malformations because there is emerging evidence that fibroblasts establish hetero-
typic contacts in vivo with myocytes that can affect myocyte growth or electro-
physiology [45]. For example, isolated CD45+ bone marrow cells could be
genetically engineered to secrete growth factors like neuregulin which has been
shown to reactivate cell cycling in mononucleated cardiomyocytes [46]. For hypo-
plastic valve or septal tissues, we have already suggested (see above) several
genetic or small molecule pharmacological remedial approaches that would be
amenable to using CD45 cells for their delivery; for example, viral transduction
of CD45+ cells could be used to overexpress or suppress any of kinase or integrin
genes known to promote or inhibit fibroblast differentiation [47, 48], focusing on
Cre-promoters that allow sharp delineation from myocytes lineages
[49, 50]. Antennapedia internalization sequences could also be used to introduce
a wide range of “cargo” peptides into isolated CD45 cells.
5.4.1 Preliminary Studies
While we have shown using chimeric mice, i.e., irradiated animals whose bone
marrow had been reconstituted with GFP+ hematopoietic stem cells, that it is
possible to track bone marrow-derived cells that give rise to bona fide fibroblasts
in the heart, it remains to be determined whether they can effectively be transduced
to carry a cargo that can have a remedial effect in injured heart tissues. As proof of
concept, we prepared a lentivirus periostin-silencing (shRNA) vector directed
against the 30 end of the periostin transcript that was shown to block periostin
protein expression (>95 %) in vitro [6, 19]. These silencing or empty control
vectors were injected directly into the bone marrow minutes prior to an acute
myocardial “cryoinjury” administered by a liquid nitrogen cooled microprobe
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directly to the left ventricle of anesthetized mice. This procedure allows for a
consistent injury of known size and location within 4 days. As shown in Fig. 5.3,
an externally visible scar (blue-white in color) developed within a week in control
cryoinjured mice, whereas in experimental cryoinjured mice in which periostin-
silencing vectors were injected into the bone marrow, the scar was barely visible
and the tissue appeared healthy and vascularized. Echocardiographic analyses were
performed at weekly intervals. Cryoinjured mice that received bone marrow
injections of the periostin-silencing vector exhibited performance metrics (e.g.,
LV vol., ejection fraction) comparable to normal mouse baseline values, whereas
those that received the empty control vector exhibited significant reduction of all
baseline values. While preliminary, we expect that bone marrow transduction will
target cells that potentially can engraft into the heart and modify connective tissue
or myocardial remodeling to benefit patient health.
Finally, as developmental biologists searching for remedial etiologies and
therapies, we believe the crux of the issue lies in shifting our focus toward
understanding that:
1. The later periods of fetal and neonatal cardiovascular development present a
window to initiate remedial therapies.
2. The interactions between multiple signaling hubs will become a priority rather
than continuing to investigate early events or single genes.
3. The heart is an integrated organ in which lineages can provide insight for
improving therapeutic outcomes for CHD through genetic or pharmacological
manipulation.
Fig. 5.3 Cryoinjured adult hearts treated with lentiviral siRNA vectors to silence periostin
injected into the bone marrow. (a) arrows denote a typical injury site 4 days after cryoablation;
after 8 weeks, a large scar (white color) is visible on the left ventricular surface which when
examined histologically reveals extensive fibrosis (blue in Masson stain, muscle is red). (b) left
panel, empty vector control showing developing scar is turning bluish due to lost vascularity and
fibrosis; right panel is a heart after bone marrow injection with periostin siRNA vector. The injury
site is barely detectable and well vascularized. Performance metrics (bottom) indicate that
silencing periostin gave results similar to those of baseline controls
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4. The complexity and balance of signals that affect processes controlling the
formation of the heart may also come into play after birth or into adult life,
where their engineered re-expression can be used to enhance or awaken the
ability of heart cells to adapt to pathophysiological stimuli engendered during
development.
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